Galectin Therapeutics (GALT) Treasury Shares (2010 - 2026)

Galectin Therapeutics' Treasury Shares history runs 17 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• In Q1 2026, Treasury Shares fell 56.52% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $4.2 million (down 56.52% YoY), while the FY2025 annual figure was $4.2 million, down 56.52% from the prior year.
• Treasury Shares for Q1 2026 stood at $4.2 million, roughly flat from $4.2 million in the prior quarter.
• The five-year high for Treasury Shares was $12.0 million in Q2 2023, with the low at $176.0 in Q4 2024.
• The 5-year median for Treasury Shares is $9.6 million (2024), against an average of $8.7 million.
• The sharpest annual moves came in 2022 and 2024: Treasury Shares soared 6566925.0% in 2022, then plunged 100.0% in 2024.
• Galectin Therapeutics' Treasury Shares stood at $11.6 million in 2022, then declined by 19.91% to $9.3 million in 2023, then slumped by 100.0% to $176.0 in 2024, then soared by 2370436.36% to $4.2 million in 2025, then changed by 0.0% to $4.2 million in 2026.
• Business Quant data shows GALT's Treasury Shares at $4.2 million in Q1 2026, $4.2 million in Q4 2025, and $4.0 million in Q3 2025.